{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:08:10Z","timestamp":1790125690847,"version":"4.0.1"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe patient characteristics, adherence, and treatment patterns, among adult migraine patients in the United States prescribed erenumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a highly prevalent and debilitating disease characterized by recurrent attacks of moderate to severe headache accompanied by non\u2010headache symptoms. Erenumab is a first\u2010in\u2010class calcitonin gene\u2010related peptide receptor (CGRP\u2010R) antagonist indicated for migraine prophylaxis in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective longitudinal cohort study used IQVIA\u2019s open\u2010source longitudinal pharmacy (LRx) and medical (Dx) claims databases to identify adult migraine patients with an initial claim (index date) for erenumab between May 1, 2018 and April 30, 2019. Patients were required to have \u2265180\u00a0days of follow\u2010up. Erenumab dosing patterns, persistence, and adherence (using medication possession ratio [MPR] and proportion of days covered [PDC]), and discontinuation of other commonly prescribed acute and prophylactic anti\u2010migraine therapies were assessed. Dose changes in acute therapies after initiation of erenumab were assessed in a subset of patients with an adequate trial of erenumab (\u22652 additional erenumab claims within the 80\u00a0days following the index claim).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 64,174 patients met the study criteria. Mean (SD) age was 48 (13) years and 85.2% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a054,656) were female. The initial erenumab dose was 70\u00a0mg for the majority of patients (65.1%;\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a041,790); most (81.4%;\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a034,019) maintained their index dose during follow\u2010up. Overall, 30.8% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a019,797) of patients had a PDC\u00a0\u2265\u00a00.80 and 41.7% (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a026,769) had a MPR\u00a0\u2265\u00a00.80. Discontinuation rates of acute and other prophylactic migraine therapies after initiation of erenumab (among users of the respective therapies) were 48.7% (22,965\/47,190) and 36.1% (16,602\/46,006), respectively. Dose decreases among triptan, ergot compound, opioid, and barbiturate users were observed after initiation of erenumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Almost all patients had prior use of acute or preventive therapy. Adherence to erenumab was higher than traditional oral prophylactic migraine therapies; however, overall adherence was still suboptimal. The decrease in use of acute and preventive prescription medications following initiation of erenumab suggests effectiveness in the real\u2010world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14068","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T04:25:27Z","timestamp":1613795127000},"page":"590-602","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Erenumab patient characteristics, medication adherence, and treatment patterns in the United States"],"prefix":"10.1111","volume":"61","author":[{"given":"Dionne M.","family":"Hines","sequence":"first","affiliation":[{"name":"Department of Health Economics and Outcomes Research IQVIA Inc. Plymouth Meeting PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Global Health Economics Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasjit K.","family":"Multani","sequence":"additional","affiliation":[{"name":"Department of Health Economics and Outcomes Research IQVIA Inc. Plymouth Meeting PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolin L.","family":"Wade","sequence":"additional","affiliation":[{"name":"Department of Health Economics and Outcomes Research IQVIA Inc. Plymouth Meeting PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[{"name":"Department of Neurology Albert Einstein College of Medicine Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bensink","sequence":"additional","affiliation":[{"name":"Formerly Department of Global Health Economics Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000323925.29520.e7"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13157"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"e_1_2_10_11_1","volume-title":"Aimovig\u00ae (Erenumab\u2010Aooe) [Package Insert]","year":"2019"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007452"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2012.00530.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14068","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:54:18Z","timestamp":1762088058000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/head.14068"],"URL":"https:\/\/doi.org\/10.1111\/head.14068","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"2020-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}